Ikarian Capital, LLC Intra Cellular Therapies, Inc. Transaction History

Ikarian Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$35.2 - $53.42 $7.45 Million - $11.3 Million	-211,670 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$28.72 - $42.49 $551,969 - $816,615	-19,219 Reduced 8.32%	211,670 $7.89 Million
Q2 2021 Aug 16, 2021	SELL	$29.3 - $44.5 $2.93 Million - $4.45 Million	-100,100 Reduced 30.24%	230,889 $9.43 Million
Q1 2021 May 17, 2021	BUY	$30.8 - $39.51 $1.54 Million - $1.98 Million	50,000 Added 17.79%	330,989 $11.2 Million
Q4 2020 Feb 12, 2021	BUY	$23.34 - $32.22 $933,600 - $1.29 Million	40,000 Added 16.6%	280,989 $8.93 Million
Q3 2020 Nov 16, 2020	BUY	$17.61 - $31.86 $4.12 Million - $7.45 Million	233,787 Added 3246.14%	240,989 $6.18 Million
Q2 2020 Aug 14, 2020	SELL	$14.35 - $26.64 $3.47 Million - $6.44 Million	-241,800 Reduced 97.11%	7,202 $185,000
Q1 2020 May 15, 2020	BUY	$12.31 - $33.12 $3.07 Million - $8.25 Million	249,002 New	249,002 $3.83 Million

380

84M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.